Dyadic International, Inc. (DYAI)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Dyadic International, Inc.
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 350K | 236K | 624K | 124K |
| Gross Profit | (674K) | (149K) | (168K) | (860K) |
| Operating Income | (1.9M) | (1.5M) | (1.9M) | (2.0M) |
| Net Income | (2.0M) | (1.6M) | (2.0M) | (2.1M) |
| Diluted EPS | $-0.06 | N/A | $-0.05 | $-0.06 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 2.9M | 2.9M | 3.5M | 1.2M |
| Gross Profit | 807K | 923K | 2.3M | (1.1M) |
| Operating Income | (10.1M) | (8.2M) | (5.9M) | (7.1M) |
| Net Income | (9.7M) | (6.8M) | (5.8M) | (7.4M) |
| Diluted EPS | $-0.34 | $-0.24 | $-0.20 | $-0.23 |